KCG
BIIB icon

Knight Capital Group’s Biogen BIIB Stock Holding History

Knight Capital Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$5.34M Buy
+24,800
New +$5.3M 0.1% 139

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Knight Capital Group's BIIB Position: Q2 2013 in Review

Knight Capital Group opened a new position in Biogen (BIIB) in Q2 2013: 7,602 shares worth $1.64M. The stake represents 0.03% of the portfolio and ranks #656 among its holdings.

646 funds tracked by Wall St. Rank hold BIIB as of Q2 2013.

  • Knight Capital Group held 7,602 shares of Biogen worth $1.64M as of Q2 2013.
  • Biogen was a new Knight Capital Group position in Q2 2013.
  • Biogen made up 0.03% of Knight Capital Group's portfolio in Q2 2013, its #656 holding.
  • 646 funds tracked by Wall St. Rank held Biogen as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.